Overview

Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure

Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of aliskiren alone and in combination with valsartan given to patients with essential hypertension
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Valsartan